Of 428 biopsy specimens, the TERT C228T mutation was detected in 9% (31/364) of NU, 27% (4/15) of UD, 50% (9/18) of UD suspicious for CIS, and 58% (18/31) of biopsy‐proven CIS. This evidence concerns the gene TERT and in situ carcinoma.